Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expanding Best-in-Class Product Line

  • Lexaria has developed an oral digestion technology that may translate into lower dosages and shorter treatment regimens
  • Company is expanding its edible product offerings through a licensing agreement with a Canadian cannabis chocolate manufacturer
  • Lexaria continues to develop products for demonstration, testing and sales

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed DehydraTECH™, an oral digestion technology believed to improve the absorption rates of nicotine, non-steroid anti-inflammatory drugs (NSAIDs), vitamins and cannabinoids by as much as five to ten times the normal rate. The time of onset is also reduced, and effects are felt within 15 to 20 minutes versus the normal 60 to 120 minutes. This proprietary technology also eliminates the undesired taste of cannabinoid edibles. By changing the way active pharmaceutical ingredients (APIs) enter the body, the user can benefit from lower dosages and quicker effects. The bioavailability of the APIs is improved, while side effects are tempered. As a result, this technology promotes far healthier ingestion methods than smoking or vaping.

Recently, the company announced its entry into a licensing agreement with Cannfections Group Inc. This agreement offers Lexaria the ability to provide commercial clients with high quality chocolate edibles. Cannfections is an infused chocolate and gummies contract manufacturer that was recently…


More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

Leave a Reply